Peripheral Blood CD34+ Cells Search Results


human peripheral blood mononuclear cells  (iXCells Biotechnologies)
91
iXCells Biotechnologies human peripheral blood mononuclear cells
Human Peripheral Blood Mononuclear Cells, supplied by iXCells Biotechnologies, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human peripheral blood mononuclear cells/product/iXCells Biotechnologies
Average 91 stars, based on 1 article reviews
human peripheral blood mononuclear cells - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
peripheral blood cd34 cells  (AMS Biotechnology)
96
AMS Biotechnology peripheral blood cd34 cells
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Peripheral Blood Cd34 Cells, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peripheral blood cd34 cells/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
peripheral blood cd34 cells - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
cd34 positive peripheral blood stem cell isolation  (Chugai)
90
Chugai cd34 positive peripheral blood stem cell isolation
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Cd34 Positive Peripheral Blood Stem Cell Isolation, supplied by Chugai, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 positive peripheral blood stem cell isolation/product/Chugai
Average 90 stars, based on 1 article reviews
cd34 positive peripheral blood stem cell isolation - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
human bone marrow cd34+ cells  (Biowhittaker Inc)
90
Biowhittaker Inc human bone marrow cd34+ cells
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Human Bone Marrow Cd34+ Cells, supplied by Biowhittaker Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human bone marrow cd34+ cells/product/Biowhittaker Inc
Average 90 stars, based on 1 article reviews
human bone marrow cd34+ cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
g-csf-mobilized human peripheral bloods cd34+ cells  (Veritas Corporation)
90
Veritas Corporation g-csf-mobilized human peripheral bloods cd34+ cells
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
G Csf Mobilized Human Peripheral Bloods Cd34+ Cells, supplied by Veritas Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/g-csf-mobilized human peripheral bloods cd34+ cells/product/Veritas Corporation
Average 90 stars, based on 1 article reviews
g-csf-mobilized human peripheral bloods cd34+ cells - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
predictive factors for poor peripheral blood stem cell mobilization and peak cd34(+) cell count  (Grifols)
90
Grifols predictive factors for poor peripheral blood stem cell mobilization and peak cd34(+) cell count
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Predictive Factors For Poor Peripheral Blood Stem Cell Mobilization And Peak Cd34(+) Cell Count, supplied by Grifols, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/predictive factors for poor peripheral blood stem cell mobilization and peak cd34(+) cell count/product/Grifols
Average 90 stars, based on 1 article reviews
predictive factors for poor peripheral blood stem cell mobilization and peak cd34(+) cell count - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
granulocyte colony stimulating factor (gcsf) induced peripheral blood derived cd34+ endothelial progenitor cells (epcs)  (Chennai Corporation)
90
Chennai Corporation granulocyte colony stimulating factor (gcsf) induced peripheral blood derived cd34+ endothelial progenitor cells (epcs)
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Granulocyte Colony Stimulating Factor (Gcsf) Induced Peripheral Blood Derived Cd34+ Endothelial Progenitor Cells (Epcs), supplied by Chennai Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/granulocyte colony stimulating factor (gcsf) induced peripheral blood derived cd34+ endothelial progenitor cells (epcs)/product/Chennai Corporation
Average 90 stars, based on 1 article reviews
granulocyte colony stimulating factor (gcsf) induced peripheral blood derived cd34+ endothelial progenitor cells (epcs) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
human cd34+ progenitor cells from mobilized peripheral blood  (Lonza)
N/A
Cryopreserved CD34+ cells, ≥ 1 million cells, isolated from mobilized peripheral blood using positive immunomagnetic selection
   Buy from Supplier
highqc human mobilized peripheral blood cd34+ stem cell  (AcceGen Biotechnology)
N/A
CD34 is a glycosylated transmembrane protein and represents a well-known marker for primitive blood-and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial stem cells. CD34+ stem cells are multipotent and can give rise to
   Buy from Supplier
highqc human mobilized peripheral blood cd34+ stem progenitor cells; g-csf and cxcr4 antagonists  (AcceGen Biotechnology)
N/A
CD34 is most commonly associated with expression on hematopoietic progenitor cells found in bone marrow and cord blood. While compromising only 1.5% of bone marrow mononuclear cell population, CD34 stem cells are multipotent and responsible
   Buy from Supplier
human mobilized peripheral blood mononuclear cells, cd34 depleted  (AcceGen Biotechnology)
N/A
CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. AcceGen offers CD34+ progenitor cells in a phenotypically undifferentiated state. The progenitor cells are derived from the
   Buy from Supplier
highqc human mobilized peripheral blood cd34+ stem progenitor cells; cxcr4 antagonists  (AcceGen Biotechnology)
N/A
CD34+ stem cells are multipotent and can give rise to all cell types in blood. CD34 cells are most known for its expression on hematopoietic progenitor cells found in bone marrow and cord blood. While
   Buy from Supplier

Image Search Results


Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy CD34 + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).

Journal: iScience

Article Title: Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

doi: 10.1016/j.isci.2024.109576

Figure Lengend Snippet: Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy CD34 + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).

Article Snippet: Human Mobilized Peripheral Blood CD34 + Cells, used as healthy controls, were purchased from AMS Biotechnology (Europe) Limited.

Techniques: Inhibition, Western Blot, Standard Deviation, Cell Culture

Journal: iScience

Article Title: Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

doi: 10.1016/j.isci.2024.109576

Figure Lengend Snippet:

Article Snippet: Human Mobilized Peripheral Blood CD34 + Cells, used as healthy controls, were purchased from AMS Biotechnology (Europe) Limited.

Techniques: Control, Virus, Recombinant, Modification, Saline, Stripping Membranes, Protease Inhibitor, Reverse Transcription, Membrane, Labeling, Gel Extraction, Plasmid Preparation, Software